MedTrace Logo

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2021-08-02

No results posted yet for this study

Summary

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.

Conditions

Interventions

DRUG

AC-1204

AC-1204 taken once daily, by mouth

DRUG

Placebo

Placebo taken once daily, by mouth

Sponsors & Collaborators

  • Cerecin

    lead INDUSTRY

Principal Investigators

  • Samuel T Henderson, PhD · Cerecin

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
66 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-10-24
Completion
2017-04-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741194 on ClinicalTrials.gov